HOME > Investor Relations > Investor Relations Digest

 

We will harness our unique attributes and strengths in the two businesses of the Self-Medication Operation Group and the Prescription Pharmaceutical Operation Group, in order to continue meeting the challenges of a new era.

Self-Medication Operation Group

The Self-Medication Operation Group has many leading brands, such as the Lipovitan series of energy drinks, the Pabron series of cold remedies, and the RiUP series of hair regrowth treatments. In these fields, the Self-Medication Operation Group is a leader in the Japanese market.

Market Trend and Company Policy

 

Prescription Pharmaceutical Operation Group

The Prescription Pharmaceutical Operation Group is pressing ahead with R&D activities focused on priority fields. At the same time, Taisho Pharmaceutical is conducting sales and marketing activities centered on the fields of infectious diseases and orthopedic disorders, and metabolic diseases field.

Market Trend and Company Policy

 

Performance

Financial Results Highlights“Net sales / Operating income

 

Performance

Financial Results Highlights“Net sales / Operating income

 

topics

Launch of new self-medication-related products

Click here for details

 

topics

Launch of new ethical drugs

Click here for details

 
Self-Medication Our Business
Prescription Pharmaceutical Our Business
IR Library